Overactive Urinary Bladder in Women and Its Association with Irritable Bowel Syndrome: A Systematic Review
Published: 2023-07-22
Page: 143-150
Issue: 2023 - Volume 6 [Issue 1]
Ibrahim Alowidah
Urology Department, King Saud Medical City, Riyadh, Saudi Arabia.
Kholood Mohmadjafarali Khan *
King Saud Medical City, Riyadh, Saudi Arabia.
Esraa Taher Mohammed Alahdal
King Fahad University Hospital, Alkhobar, Saudi Arabia.
Feras M. Allagany
King Abdulaziz University, Saudi Arabia.
Noor H. Almousa
King Saud Medical City, Riyadh, Saudi Arabia.
Mathab Ali Jarad
King Saud Medical City, Riyadh, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
Background: In the absence of a confirmed infection or other evident diseases, overactive bladder (OAB) is defined by symptoms of urgency, with or without urgency incontinence, and typically with urine frequency and nocturia.
Methods: This is an updated systematic review of studies on the prevalence, and treatment of overactive bladder and its correlation to irritable bowel syndrome between 2013 and 2022. The PubMed and Google scholar databases were used to explore studies regarding our subject.
Results: Though 110 articles were obtained, only nine met the inclusion criteria. The studies included OAB patients. Three studies were cross-sectional, two studies were retrospective cohort studies, two clinical trials, one survey study while one was an observational study.
Conclusion: There was a high prevalence of overactive bladder symptoms among Middle Eastern women. The prevalence was higher in Hispanic women. However, no racial differences were reported as a risk factor for OAB. In mothers, the number of children was a significant risk factor for either urgency or nocturia. Trans-abdominal bladder ultrasonography (TABU) was recognized as a primary method for OAB diagnosing.
Keywords: Overactive, OAB, bladder, association, irritable bowel syndrome, IBS
How to Cite
References
Link CL, Steers WD, Kusek JW, McKinlay JB. The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey. J Urol. 2011;185(3):955–963.
Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013;6(4):179–18.
Herschorn S, Kaplan SA, Sun F, Ntanios F. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? Urology. 2014;83(5):1023–1029.
Valentini FA, Marti BG, Robain G. Idiopathic and neurogenic detrusor overactivity: Do the different patterns have urodynamic characteristics related to gender or neurological condition? Int Braz J Urol. 2013;39(5):663–670.
Stewart WF, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World journal of urology. 2003 May;20:327-36.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU international. 2001;87(9):760-6.
De Giorgio R, Barbara G, Stanghellini V, Cremon C, Salvioli B, De Ponti F, et al. Diagnosis and therapy of irritable bowel syndrome. Alimentary pharmacology & therapeutics. 2004;20:10-22.
Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: Implications for therapy. Neurogastroenterology & Motility. 2006;18(1):6-17.
Kuo YC, Kuo HC. Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. International Journal of Clinical Practice. 2012;66(2):146-51.
Coyne KS, Cash B, Kopp Z, Gelhorn H, Milsom I, Berriman S, et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU international. 2011;107(2): 254-61.
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. European urology. 2019;75(6):988-1000.
Matsuzaki J, Suzuki H, Fukushima Y, Hirata K, Fukuhara S, Okada S, et al. High frequency of overlap between functional dyspepsia and overactive bladder. Neurogastroenterology & Motility. 2012;24(9):821-7.
Lai HH, Vetter J, Jain S, Andriole GL. Systemic nonurological symptoms in patients with overactive bladder. The Journal of urology. 2016;196(2):467-72.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine. 2009;6(7):e1000100.
Al Edwan G, Abdelazim MS, Salhab SE, Jamal YM, Soliman MA. The prevalence of overactive bladder symptoms in women in Algeria, Egypt, Jordan and Lebanon: A cross-sectional population-based survey. Advances in therapy. 2021;38(2):1155-67.
Al Mousa R, Albagshi S, Alabbad A, Alshamsi H, Almuslim O. Overactive bladder amongst Saudi women: Its prevalence, risk factors, and effect on quality of life. Arab Journal of Urology. 2018;16(sup1):S4.
Mckellar K, Bellin E, Schoenbaum E, Abraham N. Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population. Urology. 2019;126:70-5.
Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. European urology. 2020;77(1):119-28.
Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU international. 2017;120(4):562-75.
Georgescu D, Petre I, Schiller A, Georgescu LA. Bladder ultrasonography as first step noninvasive approach in female patients with irritable bowel syndrome and overactive bladder. Ultrasound in Medicine & Biology. 2022;48:S46.
Kim KS, Kim HJ, Lee SH, Cho ST, Moon HS. Association between irritable bowel syndrome and overactive bladder: A research survey. Urology. 2017;109:88-93.
Matsumoto S, Hashizume K, Wada N, Hori J, Tamaki G, Kita M, et al. Relationship between overactive bladder and irritable bowel syndrome: A large‐scale internet survey in J apan using the overactive bladder symptom score and Rome III criteria. BJU international. 2013; 111(4):647-5
Persson R, Wensaas KA, Hanevik K, Eide GE, Langeland N, Rortveit G. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC gastroenterology. 2015;15(1):1-7.
D'Ancona C, Haylen B, Oelke M, Abranches‐Monteiro L, Arnold E, Goldman H, et al. A. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourology and urodynamics. 2019;38(2):433-77.
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132–8.
Funada S, Kawaguchi T, Terada N, Negoro H, Tabara Y, Kosugi S, et al. Cross-sectional epidemiological analysis of the Nagahama study for correlates of overactive bladder: genetic and environmental considerations. The Journal of Urology. 2018;199(3):774-8.
Chuang YC, Liu SP, Lee KS, Liao L, Wang J, Yoo TK, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross‐sectional, population‐based study. LUTS: Lower Urinary Tract Symptoms. 2019;11(1): 48-55.
Nickel JC, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. The Journal of urology. 2010;184(4):1358-63.
El-Azab A. Clinical and epidemiological criteria of overactive bladder (OAB) among women: A population based study; 2007.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU international. 2001;87(9):760-6.
White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: Analysis of an integrated clinical trial database of patients with overactive bladder syndrome. Journal of the American Society of Hypertension. 2018;12(11):768-78.
Astellas Pharma US Inc. VESIcare® Prescribing Information; 2016.
Available:https://www.astellas.us/docs/vesicare.pdf
Accessed May 2017
Krauwinkel WJ, Kerbusch VM, Meijer J, Tretter R, Strabach G, Van Gelderen EM. Evaluation of the pharmacokinetic interaction between the β3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:255– 63.
Oelke M, Hofner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: Detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol. 2007;52:827–34.
Jequier S, Rousseau O. Sonographic measurements of the normal bladder wall in children. AJR Am J Roentgenol. 1987;149:563–6.
Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986;27: 37–40.
Bullones Rodriguez MA, Afari N, Buchwald DS. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol. 2013;189:019.
Christianson JA, Liang R, Ustinova EE, Davis BM, Fraser MO, Pezzone MA. Convergence of bladder and colon sensory innervation occurs at the primary afferent level. Pain. 2007;128(3):235-43.
Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130(1):34-43.